Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 13;2(3):200-209.
doi: 10.1182/bloodadvances.2017010694.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Surbhi Shah  1 , Faye L Norby  2 , Yvonne H Datta  1 , Pamela L Lutsey  2 , Richard F MacLehose  2 , Lin Y Chen  1 , Alvaro Alonso  3
Affiliations

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Surbhi Shah et al. Blood Adv. .

Abstract

Randomized clinical trials comparing direct oral anticoagulants (DOACs) to warfarin in cancer patients have not been performed. We evaluated the effectiveness and associated risk of DOACs vs warfarin, as well as comparisons of DOACs, in a large population of cancer patients with nonvalvular atrial fibrillation (AF). Using the MarketScan databases, we identified 16 096 AF patients (mean age, 74 years) initiating oral anticoagulant and being actively treated for cancer between 2010 and 2014. Anticoagulant users were matched by age, sex, enrollment date, and drug initiation date. Study end points were identified with diagnostic codes and included ischemic stroke, severe bleeding, other bleeding, and venous thromboembolism (VTE). Cox regression was used to estimate associations of anticoagulants with study end points. Compared with warfarin, rates of bleeding (hazard ratio [95% confidence interval]) were similar in rivaroxaban (1.09 [0.79, 1.39]) and dabigatran (0.96 [0.72, 1.27]) users, whereas apixaban users experienced lower rates (0.37 [0.17, 0.79]). Rates of ischemic stroke did not differ among anticoagulant users. Compared with warfarin, rate of VTE (hazard ratio [95% confidence interval]) was lower among rivaroxaban (0.51 [0.41, 0.63]), dabigatran (0.28 [0.21, 0.38]), and apixaban (0.14 [0.07, 0.32]) users. In head-to-head comparisons among DOACs, dabigatran users had lower rates of VTE than rivaroxaban users; apixaban users had lower rates of VTE and severe bleeding than rivaroxaban users. In this population of patients with AF and cancer, DOAC users experienced lower or similar rates of bleeding and stroke compared with warfarin users, and a lower rate of incident VTE.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
Professional illustration by Patrick Lane, ScEYEnce Studios
Figure 1.
Figure 1.
Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: rivaroxaban vs warfarin users.
Figure 2.
Figure 2.
Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: dabigatran vs warfarin users.
Figure 3.
Figure 3.
Adjusted HRs (95% CIs) of outcomes among anticoagulant users, stratified by subgroups: apixaban vs warfarin users.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712-1723. - PubMed
    1. Prandoni P, Lensing AW, Piccioli A, et al. . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488. - PubMed
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. - PubMed
    1. Patel MR, Mahaffey KW, Garg J, et al. ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. - PubMed
    1. Granger CB, Alexander JH, McMurray JJV, et al. ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. - PubMed

Publication types

MeSH terms